Once we see the peer review, which I expect to cover more data than we see in the press releases, it may also address different strains it could target.
We're in the right place imo. I'm looking mid to late August for more solid info.
....
...
Putting all this together should make for quite an impressive peer review. And I HIGHLY DOUBT it would go unnoticed.
We're in the right place imo. I'm looking mid to late August for more solid info.
Quote:... consistently demonstrated robust in vitro antiviral properties against SARS-CoV-2, the novel coronavirus responsible for COVID-19.
Most recently, Brilacidin exhibited a statistically significant (p<0.0001) and potent inhibitory effect on SARS-CoV-2 in a human lung epithelial cell line, reducing viral load by up to 97% compared to control.
... in vitro data that compares a drug’s cytotoxicity and antiviral activity. The higher the SI ratio, the more effective and safe a drug has the potential to be in the clinic.
http://www.ipharminc.com/press-release/2020/7...ical-trial
....
Quote:Brilacidin exhibited a statistically significant (p<0.0001) and potent inhibitory effect on SARS-CoV-2, the novel coronavirus responsible for COVID-19, in a human lung epithelial cell line—reducing viral load by 95 percent and by 97 percent, compared to control, at two therapeutic concentrations tested. Based on a CC50 value—the concentration of drug at which 50 percent of cells maintain viability—Brilacidin was also shown to be non-cytotoxic in the lung cell line.
The new lung cell line data reinforce previous testing conducted at the RBL, in VERO cells, where Brilacidin showed a similar robust inhibition, of 75 percent, against SARS-CoV-2 compared to control. Brilacidin has also been shown, in testing at the RBL, to be non-cytotoxic in VERO cells.
http://www.ipharminc.com/press-release/2020/6...-cell-line
...
Quote:U.S. Regional Biocontainment Laboratory (RBL) are collaborating on a federal grant application to be submitted this week.
The proposed research aims to evaluate Brilacidin as a potential pan-coronavirus therapeutic, for treating SARS-CoV-2, SARS-CoV-1 and MERS-CoV, including extending the current in vitro testing of Brilacidin to in vivo testing. Longer-term objectives include potentially performing additional research to develop Brilacidin as a broad-spectrum antiviral, with possible application beyond coronaviruses, e.g., treating other viruses, such as encephalitic alphaviruses and filoviruses.
The ongoing Brilacidin anti-SARS-CoV-2 research being conducted at the RBL is separate from the ongoing research being performed at a Public Health Research Institute (PHRI). The lead researchers at both the RBL and at the PHRI have informed the Company they plan to submit their findings, separately, upon completion of in vitro testing, for peer-review publication.
http://www.ipharminc.com/press-release/2020/6...herapeutic
Quote:receiving data from a leading Public Health Research Institute (PHRI) showing Brilacidin inhibits SARS-CoV-2, the novel coronavirus responsible for COVID-19, in a human cell line. Brilacidin, in comparison to vehicle control, exhibited an inhibitory effect on SARS-CoV-2 in a dose-dependent manner—an average 29 percent inhibition at 0.1ug/ml (the lowest concentration) to an 85 percent inhibition at 100ug/ml (the highest concentration).
The Brilacidin anti-SARS-CoV-2 research being conducted at the PHRI is separate from research being performed at a U.S. Regional Biocontainment Laboratory (RBL), both with BSL-3 testing capabilities.
“This human cell line data is highly significant, with exciting implications,” commented Leo Ehrlich, Chief Executive Officer at Innovation Pharmaceuticals. “We now have preliminary in vitro data from two separate independent laboratories that, cumulatively, support Brilacidin’s ability to act directly on the novel coronavirus, as a virucidal agent, and prevent viral binding to host cells. Across the coming weeks, we anticipate sharing additional anti-SARS-CoV-2 data from both research institutions as we work towards initiating a clinical study of Brilacidin for the treatment of COVID-19.”
For the experiment, the SARS-CoV-2 spike pseudotyped luciferase virus was incubated with Brilacidin at different concentrations—from a low of 0.1ug/ml to a high of 100ug/ml—for 1 hour before being added to HEK/293T cells (a human kidney cell line) expressing hACE2 for 2 hours. Then, the infected cells were cultured in media for 3 days before cells were lysed, with the inhibitory effect measured as a function of luciferase activity. Multiple measurements were taken to determine an average efficacy.
The primary investigator characterized the results as promising, especially given inhibitory effects in this particular human cell line are difficult to achieve based on the PHRI’s experience testing other defensins. The researcher also theorizes Brilacidin’s inhibitory effect may be partially due to the drug’s ability to prevent viral entry by blocking the SARS-CoV-2 Spike 1 (S1) Receptor-Binding Domain (RBD) from interacting with the Angiotensin-Converting Enzyme-2 (ACE2) receptor, the method by which the novel coronavirus gains entry into human cells. Additional anti-SARS-CoV-2 testing in human cell lines is underway at both the PHRI and the RBL to further elucidate Brilacidin’s antiviral properties.
http://www.ipharminc.com/press-release/2020/5...-cell-line
Putting all this together should make for quite an impressive peer review. And I HIGHLY DOUBT it would go unnoticed.
2
